Favorable outcome of COVID-19 in a young woman with severe Crohn’s disease on regular use of adalimumab and prednisone: a case report

Detalhes bibliográficos
Autor(a) principal: Vechi, Hareton Teixeira
Data de Publicação: 2020
Outros Autores: Maia, Lucas Rodrigues, Alves, Manoela do Monte, Rodrigues-Neto, João Firmino
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Repositório Institucional da UFRN
Texto Completo: https://repositorio.ufrn.br/handle/123456789/46067
Resumo: COVID-19 is a viral disease caused by SARS-CoV-2 that compromises the host immune response in severe cases, promoting a hyperinflammation that results in acute lung injury and multiple organs failure. In this context, patients presenting with immune-related diseases, such as Crohn’s disease, affected by COVID-19, may have an uncertain prognosis. We report on a case of a young female patient with a severe Crohn’s disease that presented with COVID-19 pneumonia and a favorable outcome even maintaining the use of adalimumab, TNF - alpha inhibitor and prednisone. This case raises the hypothesis that aside from prednisone, TNF-α inhibitors such as adalimumab could be used to stop the progression to COVID-19 complications by blocking the TNF-alpha-driven inflammatory process that occurs in severe COVID-19
id UFRN_f3d02140c46b2cd2db039919ac165665
oai_identifier_str oai:https://repositorio.ufrn.br:123456789/46067
network_acronym_str UFRN
network_name_str Repositório Institucional da UFRN
repository_id_str
spelling Vechi, Hareton TeixeiraMaia, Lucas RodriguesAlves, Manoela do MonteRodrigues-Neto, João Firmino2022-02-18T11:10:29Z2022-02-18T11:10:29Z2020VECHI, Hareton Teixeira et al. Favorable outcome of COVID-19 in a young woman with severe Crohn’s disease on regular use of adalimumab and prednisone: a case report. Revista do Instituto de Medicina Tropical de São Paulo, [s. l.], v. 62, p. 1-6, 2020. Disponível em: https://www.scielo.br/j/rimtsp/a/G39mZmZfxz3Xnqkn3ff8fby/?lang=en. Acesso em: 16 fev. 2022. http://dx.doi.org/10.1590/s1678-99462020621021678-9946 (online)0036-4665 (print)https://repositorio.ufrn.br/handle/123456789/4606710.1590/s1678-9946202062102Universidade de São Paulo (USP)Attribution-NonCommercial 3.0 Brazilhttp://creativecommons.org/licenses/by-nc/3.0/br/info:eu-repo/semantics/openAccessCOVID-19Crohn’s diseaseTNF inhibitorSARS-CoV-2Favorable outcome of COVID-19 in a young woman with severe Crohn’s disease on regular use of adalimumab and prednisone: a case reportinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleCOVID-19 is a viral disease caused by SARS-CoV-2 that compromises the host immune response in severe cases, promoting a hyperinflammation that results in acute lung injury and multiple organs failure. In this context, patients presenting with immune-related diseases, such as Crohn’s disease, affected by COVID-19, may have an uncertain prognosis. We report on a case of a young female patient with a severe Crohn’s disease that presented with COVID-19 pneumonia and a favorable outcome even maintaining the use of adalimumab, TNF - alpha inhibitor and prednisone. This case raises the hypothesis that aside from prednisone, TNF-α inhibitors such as adalimumab could be used to stop the progression to COVID-19 complications by blocking the TNF-alpha-driven inflammatory process that occurs in severe COVID-19engreponame:Repositório Institucional da UFRNinstname:Universidade Federal do Rio Grande do Norte (UFRN)instacron:UFRNORIGINALFavorableOutcomeCovid-19_Vechi_2020.pdfFavorableOutcomeCovid-19_Vechi_2020.pdfapplication/pdf615421https://repositorio.ufrn.br/bitstream/123456789/46067/1/FavorableOutcomeCovid-19_Vechi_2020.pdf8fb658f0c527f895a557e1a84bb10374MD51CC-LICENSElicense_rdflicense_rdfapplication/rdf+xml; charset=utf-8920https://repositorio.ufrn.br/bitstream/123456789/46067/2/license_rdf728dfda2fa81b274c619d08d1dfc1a03MD52LICENSElicense.txtlicense.txttext/plain; charset=utf-81484https://repositorio.ufrn.br/bitstream/123456789/46067/3/license.txte9597aa2854d128fd968be5edc8a28d9MD53123456789/460672022-02-18 08:10:29.447oai:https://repositorio.ufrn.br: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Repositório de PublicaçõesPUBhttp://repositorio.ufrn.br/oai/opendoar:2022-02-18T11:10:29Repositório Institucional da UFRN - Universidade Federal do Rio Grande do Norte (UFRN)false
dc.title.pt_BR.fl_str_mv Favorable outcome of COVID-19 in a young woman with severe Crohn’s disease on regular use of adalimumab and prednisone: a case report
title Favorable outcome of COVID-19 in a young woman with severe Crohn’s disease on regular use of adalimumab and prednisone: a case report
spellingShingle Favorable outcome of COVID-19 in a young woman with severe Crohn’s disease on regular use of adalimumab and prednisone: a case report
Vechi, Hareton Teixeira
COVID-19
Crohn’s disease
TNF inhibitor
SARS-CoV-2
title_short Favorable outcome of COVID-19 in a young woman with severe Crohn’s disease on regular use of adalimumab and prednisone: a case report
title_full Favorable outcome of COVID-19 in a young woman with severe Crohn’s disease on regular use of adalimumab and prednisone: a case report
title_fullStr Favorable outcome of COVID-19 in a young woman with severe Crohn’s disease on regular use of adalimumab and prednisone: a case report
title_full_unstemmed Favorable outcome of COVID-19 in a young woman with severe Crohn’s disease on regular use of adalimumab and prednisone: a case report
title_sort Favorable outcome of COVID-19 in a young woman with severe Crohn’s disease on regular use of adalimumab and prednisone: a case report
author Vechi, Hareton Teixeira
author_facet Vechi, Hareton Teixeira
Maia, Lucas Rodrigues
Alves, Manoela do Monte
Rodrigues-Neto, João Firmino
author_role author
author2 Maia, Lucas Rodrigues
Alves, Manoela do Monte
Rodrigues-Neto, João Firmino
author2_role author
author
author
dc.contributor.author.fl_str_mv Vechi, Hareton Teixeira
Maia, Lucas Rodrigues
Alves, Manoela do Monte
Rodrigues-Neto, João Firmino
dc.subject.por.fl_str_mv COVID-19
Crohn’s disease
TNF inhibitor
SARS-CoV-2
topic COVID-19
Crohn’s disease
TNF inhibitor
SARS-CoV-2
description COVID-19 is a viral disease caused by SARS-CoV-2 that compromises the host immune response in severe cases, promoting a hyperinflammation that results in acute lung injury and multiple organs failure. In this context, patients presenting with immune-related diseases, such as Crohn’s disease, affected by COVID-19, may have an uncertain prognosis. We report on a case of a young female patient with a severe Crohn’s disease that presented with COVID-19 pneumonia and a favorable outcome even maintaining the use of adalimumab, TNF - alpha inhibitor and prednisone. This case raises the hypothesis that aside from prednisone, TNF-α inhibitors such as adalimumab could be used to stop the progression to COVID-19 complications by blocking the TNF-alpha-driven inflammatory process that occurs in severe COVID-19
publishDate 2020
dc.date.issued.fl_str_mv 2020
dc.date.accessioned.fl_str_mv 2022-02-18T11:10:29Z
dc.date.available.fl_str_mv 2022-02-18T11:10:29Z
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
format article
status_str publishedVersion
dc.identifier.citation.fl_str_mv VECHI, Hareton Teixeira et al. Favorable outcome of COVID-19 in a young woman with severe Crohn’s disease on regular use of adalimumab and prednisone: a case report. Revista do Instituto de Medicina Tropical de São Paulo, [s. l.], v. 62, p. 1-6, 2020. Disponível em: https://www.scielo.br/j/rimtsp/a/G39mZmZfxz3Xnqkn3ff8fby/?lang=en. Acesso em: 16 fev. 2022. http://dx.doi.org/10.1590/s1678-9946202062102
dc.identifier.uri.fl_str_mv https://repositorio.ufrn.br/handle/123456789/46067
dc.identifier.issn.none.fl_str_mv 1678-9946 (online)
0036-4665 (print)
dc.identifier.doi.none.fl_str_mv 10.1590/s1678-9946202062102
identifier_str_mv VECHI, Hareton Teixeira et al. Favorable outcome of COVID-19 in a young woman with severe Crohn’s disease on regular use of adalimumab and prednisone: a case report. Revista do Instituto de Medicina Tropical de São Paulo, [s. l.], v. 62, p. 1-6, 2020. Disponível em: https://www.scielo.br/j/rimtsp/a/G39mZmZfxz3Xnqkn3ff8fby/?lang=en. Acesso em: 16 fev. 2022. http://dx.doi.org/10.1590/s1678-9946202062102
1678-9946 (online)
0036-4665 (print)
10.1590/s1678-9946202062102
url https://repositorio.ufrn.br/handle/123456789/46067
dc.language.iso.fl_str_mv eng
language eng
dc.rights.driver.fl_str_mv Attribution-NonCommercial 3.0 Brazil
http://creativecommons.org/licenses/by-nc/3.0/br/
info:eu-repo/semantics/openAccess
rights_invalid_str_mv Attribution-NonCommercial 3.0 Brazil
http://creativecommons.org/licenses/by-nc/3.0/br/
eu_rights_str_mv openAccess
dc.publisher.none.fl_str_mv Universidade de São Paulo (USP)
publisher.none.fl_str_mv Universidade de São Paulo (USP)
dc.source.none.fl_str_mv reponame:Repositório Institucional da UFRN
instname:Universidade Federal do Rio Grande do Norte (UFRN)
instacron:UFRN
instname_str Universidade Federal do Rio Grande do Norte (UFRN)
instacron_str UFRN
institution UFRN
reponame_str Repositório Institucional da UFRN
collection Repositório Institucional da UFRN
bitstream.url.fl_str_mv https://repositorio.ufrn.br/bitstream/123456789/46067/1/FavorableOutcomeCovid-19_Vechi_2020.pdf
https://repositorio.ufrn.br/bitstream/123456789/46067/2/license_rdf
https://repositorio.ufrn.br/bitstream/123456789/46067/3/license.txt
bitstream.checksum.fl_str_mv 8fb658f0c527f895a557e1a84bb10374
728dfda2fa81b274c619d08d1dfc1a03
e9597aa2854d128fd968be5edc8a28d9
bitstream.checksumAlgorithm.fl_str_mv MD5
MD5
MD5
repository.name.fl_str_mv Repositório Institucional da UFRN - Universidade Federal do Rio Grande do Norte (UFRN)
repository.mail.fl_str_mv
_version_ 1802117799186792448

Registros relacionados